Cabaletta has been evaluating the CAR-T, called resecabtagene autoleucel or rese-cel , across six so-called RESET studies ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced its financial results for the fourth quarter and full ...

FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –– Enrolling approximately one patient per week ...

myositis, vasculitis, and myasthenia gravis; the expected cost associated with and impact of the restructuring; and Nkarta’s expected cash runway. Because such statements are subject to risks and ...

Treatment with inebilizumab was associated with continued improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) generalized myasthenia gravis (gMG), according to 52-week ...

Cabaletta is testing this approach in the clinic with its Phase I/II RESET program, which is assessing rese-cel in a wide variety of autoimmune disorders, including myositis, SLE, systemic sclerosis, ...

The Tensilon test was discontinued in the U.S. in 2018. It was performed to help diagnose myasthenia gravis (MG), a neuromuscular junction condition characterized by muscle weakness. The test involved ...

Generalised myasthenia gravis (gMG) is a chronic disorder in which the body's immune system mistakenly targets the neuromuscular junctions—areas where nerves signal muscles to move. This ...

With what analysts are calling “strong” data, Amgen plans to file a regulatory submission for Uplizna, currently approved for a rare ocular autoimmune disorder, in myasthenia gravis, in the first half ...

March 11, 2025 -- The FDA has approved a new treatment for children with generalized myasthenia gravis (gMG), a disease that makes muscles weak and tired quickly. This is the first and only ...